GSK plc
GLAXF · OTC
10/28/2025 | 9/30/2025 | 6/30/2025 | 3/31/2025 | |
|---|---|---|---|---|
| Revenue | $8,547 | – | $7,986 | $7,516 |
| % Growth | – | – | 6.3% | – |
| Cost of Goods Sold | $2,258 | – | $2,165 | $1,937 |
| Gross Profit | $6,289 | – | $5,821 | $5,579 |
| % Margin | 73.6% | – | 72.9% | 74.2% |
| R&D Expenses | $1,689 | – | $2,024 | $1,462 |
| G&A Expenses | $2,239 | – | $2,140 | $2,070 |
| SG&A Expenses | $2,239 | – | $2,140 | $2,070 |
| Sales & Mktg Exp. | $0 | – | $0 | $0 |
| Other Operating Expenses | -$232 | – | -$366 | -$169 |
| Operating Expenses | $3,696 | – | $3,798 | $3,363 |
| Operating Income | $2,593 | – | $2,023 | $2,216 |
| % Margin | 30.3% | – | 25.3% | 29.5% |
| Other Income/Exp. Net | -$137 | – | -$136 | -$108 |
| Pre-Tax Income | $2,456 | – | $1,887 | $2,108 |
| Tax Expense | $312 | – | $241 | $336 |
| Net Income | $2,013 | – | $1,443 | $1,624 |
| % Margin | 23.6% | – | 18.1% | 21.6% |
| EPS | 2.86 | – | 0.36 | 0.4 |
| % Growth | – | – | -10% | – |
| EPS Diluted | 2.82 | – | 0.35 | 0.39 |
| Weighted Avg Shares Out | 4,034 | – | 4,063 | 4,088 |
| Weighted Avg Shares Out Dil | 4,102 | – | 4,110 | 4,137 |
| Supplemental Information | – | – | – | – |
| Interest Income | $26 | – | $50 | $54 |
| Interest Expense | $167 | – | $184 | $162 |
| Depreciation & Amortization | $738 | – | $1,159 | $823 |
| EBITDA | $3,361 | – | $3,230 | $3,093 |
| % Margin | 39.3% | – | 40.4% | 41.2% |